Analyst Price Targets — NVCT
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| September 1, 2026 10:12 am | Elemer Piros | Loop Capital Markets | $40.00 | $22.73 | StreetInsider | Lucid Capital Markets Assumes Nuvectis Pharma (NVCT) at Buy |
| July 6, 2026 12:55 am | — | UBS | $33.00 | $19.57 | TheFly | Nuvectis Pharma price target raised to $33 from $20 at Roth Capital |
| June 22, 2026 3:00 pm | — | H.C. Wainwright | $39.00 | $14.96 | TheFly | Nuvectis Pharma price target raised to $39 from $13 at H.C. Wainwright |
| June 12, 2026 4:06 pm | — | H.C. Wainwright | $13.00 | $10.67 | TheFly | Nuvectis Pharma price target raised to $13 from $10 at H.C. Wainwright |
| August 4, 2025 1:55 pm | — | H.C. Wainwright | $10.00 | $7.29 | TheFly | Nuvectis Pharma price target lowered to $10 from $15 at H.C. Wainwright |
Latest News for NVCT
NVCT's 97% three-month gain reflects optimism around its expanding pipeline, with NXP100 and NXP200 offering new value drivers.
FORT LEE, N.J., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative therapies for the treatment of complement-related conditions and oncology, today reported its financial results for the second quarter of 2026 and provided an update on recent business progress.
The mean of analysts' price targets for Nuvectis Pharma (NVCT) points to a 56.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
First global approval of a once-daily, orally administered, Complement Factor B inhibitor Approval based on robust efficacy and safety data from Haisco's broad completed clinical development program in PNH Ciprocopan application for marketing approval in China for the treatment of patients with PNH previously treated with anti-C5 therapies is currently under review Ciprocopan has the potential to become an effective…
Fort Lee, NJ, July 23, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) (“Nuvectis” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of innovative therapies for the treatment of complement-related conditions and oncology, today announced that ciprocopan (NXP100), a once-daily oral complement Factor B inhibitor, received marketing approval from the National…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for NVCT.
U.S. House Trading
No House trades found for NVCT.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.